Tailored chemo doses may help seniors fight pancreatic cancer while staying independent
NCT ID NCT02143219
First seen Apr 25, 2026 · Last updated Jun 19, 2026 · Updated 9 times
Summary
This study tested a chemotherapy cocktail called FOLFIRINOX in 72 patients aged 70 or older with metastatic pancreatic cancer. The doses were adjusted based on each person's genetics to reduce side effects while still fighting the tumor. The goal was to see if this approach could control the cancer and help patients maintain their ability to perform daily activities.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CH Vendée
La Roche-sur-Yon, 85925, France
-
Centre Eugène marquis
Rennes, 35042, France
-
Centre Oscar Lambret
Lille, 59020, France
-
ICM (Val d'Aurelle)
Montpellier, 34298, France
-
ICO Paul Papin
Angers, 49000, France
-
ICO René Gauducheau
Saint-Herblain, 44805, France
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.